Compare Incyte Corporation (INCY) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares TIPS Bond ETF — how do they compare? Incyte Corporation trades at $113.77 (market cap $22.85B), while iShares TIPS Bond ETF trades at $104.41 (market cap $14.17B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and iShares TIPS Bond ETF for 61 Days on average.
| INCY | TIP | |
|---|---|---|
Market Cap | $22.85B | $14.17B |
Volume | 1,927,029 | 1,780,688 |
Sector | Health | Fixed Income |
52-Week High | $129.93 | $112.20 |
52-Week Low | $83.80 | $103.98 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
TIP trades at $104.24 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling caution while oscillators remain neutral. The ETF faces headwinds from rising bond yields and inflationary pressures affecting fixed income markets. Recent institutional activity shows Envestnet Asset Management increased its stake by 3.5% in the latest quarter.
The outlook remains challenging amid persistent bond market volatility and rising interest rates. Investment opportunity exists for inflation-protected exposure, though risks include continued yield increases and geopolitical tensions driving oil prices higher. Current technical weakness suggests cautious positioning may be warranted until market conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
